CDK4/6 inhibitors for hormone receptor-positive HER2-negative metastatic breast cancer: does one size fit all?

被引：0

作者：

Fedele, Palma ^{[1
]}

Cinieri, Saverio ^{[1
]}

机构：

[1] A Perrino Hosp, Med Oncol & Breast Unit, Brindisi, Italy

来源：

FUTURE MEDICINAL CHEMISTRY | 2019年 / 11卷 / 11期

关键词：

CDK4/6; inhibitors; endocrine resistance; endocrine therapy; metastatic breast cancer; DOUBLE-BLIND; FULVESTRANT; THERAPY; ABEMACICLIB; PALBOCICLIB;

D O I：

10.4155/fmc-2018-0389

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：1237 / 1239

页数：3

共 14 条

[1] Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG) [J].

Abraham, Jame ;

Coleman, Robert ;

Elias, Anthony ;

Holmes, Frankie Ann ;

Kalinsky, Kevin ;

Kittaneh, Muaiad ;

Lower, Elyse ;

Mahtani, Reshma ;

Mamounas, E. Terry ;

Pegram, Mark ;

Vogel, Charles .

BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) :11-20

[2] Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance [J].

Chen, Ping ;

Lee, Nathan V. ;

Hu, Wenyue ;

Xu, Meirong ;

Ferre, Rose Ann ;

Lam, Hieu ;

Bergqvist, Simon ;

Solowiej, James ;

Diehl, Wade ;

He, You-Ai ;

Yu, Xiu ;

Nagata, Asako ;

VanArsdale, Todd ;

Murray, Brion W. .

MOLECULAR CANCER THERAPEUTICS, 2016, 15 (10) :2273-2281

[3] Endocrine resistance in breast cancer - An overview and update [J].

Clarke, Robert ;

Tyson, John J. ;

Dixon, J. Michael .

MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2015, 418 :220-234

[4] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [J].

Cristofanilli, Massimo ;

Turner, Nicholas C. ;

Bondarenko, Igor ;

Ro, Jungsil ;

Im, Seock-Ah ;

Masuda, Norikazu ;

Colleoni, Marco ;

DeMichele, Angela ;

Loi, Sherene ;

Verma, Sunil ;

Iwata, Hiroji ;

Harbeck, Nadia ;

Zhang, Ke ;

Theall, Kathy Puyana ;

Jiang, Yuqiu ;

Bartlett, Cynthia Huang ;

Koehler, Maria ;

Slamon, Dennis .

LANCET ONCOLOGY, 2016, 17 (04) :425-439

[5] Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer [J].

Fedele, Palma ;

Orlando, Laura ;

Schiavone, Paola ;

Calvani, Nicola ;

Caliolo, Chiara ;

Quaranta, Annamaria ;

Nacci, Angelo ;

Cinieri, Saverio .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 94 (03) :291-301

[6] Palbociclib and Letrozole in Advanced Breast Cancer [J].

Finn, Richard S. ;

Martin, Miguel ;

Rugo, Hope S. ;

Jones, Stephen ;

Im, Seock-Ah ;

Gelmon, Karen ;

Harbeck, Nadia ;

Lipatov, Oleg N. ;

Walshe, Janice M. ;

Moulder, Stacy ;

Gauthier, Eric ;

Lu, Dongrui R. ;

Randolph, Sophia ;

Dieras, Veronique ;

Slamon, Dennis J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) :1925-1936

[7] MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer [J].

Goetz, Matthew P. ;

Toi, Masakazu ;

Campone, Mario ;

Sohn, Joohyuk ;

Paluch-Shimon, Shani ;

Huober, Jens ;

Park, In Hae ;

Tredan, Olivier ;

Chen, Shin-Cheh ;

Manso, Luis ;

Freedman, Orit C. ;

Jaliffe, Georgina Garnica ;

Forrester, Tammy ;

Frenzel, Martin ;

Barriga, Susana ;

Smith, Ian C. ;

Bourayou, Nawel ;

Di Leo, Angelo .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (32) :3638-+

[8] Targeting CDK4/6 in patients with cancer [J].

Hamilton, Erika ;

Infante, Jeffrey R. .

CANCER TREATMENT REVIEWS, 2016, 45 :129-138

[9] Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer [J].

Hortobagyi, G. N. ;

Stemmer, S. M. ;

Burris, H. A. ;

Yap, Y. -S. ;

Sonke, G. S. ;

Paluch-Shimon, S. ;

Campone, M. ;

Blackwell, K. L. ;

Andre, F. ;

Winer, E. P. ;

Janni, W. ;

Verma, S. ;

Conte, P. ;

Arteaga, C. L. ;

Cameron, D. A. ;

Petrakova, K. ;

Hart, L. L. ;

Villanueva, C. ;

Chan, A. ;

Jakobsen, E. ;

Nusch, A. ;

Burdaeva, O. ;

Grischke, E. -M. ;

Alba, E. ;

Wist, E. ;

Marschner, N. ;

Favret, A. M. ;

Yardley, D. ;

Bachelot, T. ;

Tseng, L. -M. ;

Blau, S. ;

Xuan, F. ;

Souami, F. ;

Miller, M. ;

Germa, C. ;

Hirawat, S. ;

O'Shaughnessy, J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18) :1738-1748

[10] The Role of CDK4/6 Inhibition in Breast Cancer [J].

Murphy, Conleth G. ;

Dickler, Maura N. .

ONCOLOGIST, 2015, 20 (05) :483-U49

← 1 2 →